 After obtaining informed consent Visit 1, participants undergo various assessments, including painquality-of-life analyses SF-MPQ, SF-36, VAS, physicalneurological exam and a standard blood test. Based on above inclusion criteria, participants will be randomized to either Group A paroxetine or Group B pregabalin. Participants will be provided with prescriptions for assigned study medications as well as dosing instructions. A pain diary consisting of a single VAS scale will be provided to the participants, which are to be completed daily upon waking and should be used to rate the individuals average pain over the last 24 hours. Dosages of study medications will be titrated slowly over 3 weeks to lower likelihood of adverse events. After the three week titration phase, participants will return to the clinic Visit 2 for a follow-up. Painquality-of-life assessments as at Visit 1 will be completed again at this visit. In addition, average pain scores will be determined from daily pain diaries. Adverse events will be discussed and individual tolerability will be assessed. At this point, it will be determined if the patient will be maintained at the target dosage or if the dosage will be lowered to accommodate patient tolerability. Participants will be maintained at determined maintenance dose for 5 weeks, after which they will return to the clinic Visit 3 for a final follow-up assessment. Participants will complete final painquality-of-life assessments, as well as the Patient-rated Global Impression of Change. Adverse events and average pain scores will be reviewed. At the conclusion of the 8-week treatment phase, participants will have the option of remaining on their current study medication or be tapered off. 